Genisphere, MultiCell Technologies deal

The companies partnered to evaluate the use of Genisphere's 3DNA Dendrimer nanoparticle drug delivery technology with MultiCell's MCT-485 to treat hepatocellular carcinoma (HCC). The companies said they will develop and test in animal models formulations that are safe enough to allow parenteral IV or topical administration; achieve an increased bioavailability within a tumor and tumor cells; and contain a synthetic microRNA with one or more immune modeling and cytotoxic modes of action. MultiCell declined to disclose details, and Genisphere could not be reached. ...